Download Image
    
Share
  
Post
Obefazimod for COVID-19
1 study with 305 patients
Hospital Icon Control
Hospital Icon Obefazimod Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Obefazimod studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -101% Mortality -101% RCTs -101% Late -101% Favorsobefazimod Favorscontrol
Recent:
Giavina-Bianchi.
Nov 30
2023
 Giavina-Bianchi et al., Journal of Allergy and Clinical Immunology: Global, doi:10.1016/j.jacig.2023.100140 ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
26% higher ventilation (p=0.81) and 139% higher need for oxygen therapy (p=0.11). RCT 509 patients with COVID-19 at risk for severe disease showing no benefit with obefazimod (ABX464) 50mg daily for 28 days.